research Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
Search
for
Sort by
Research
2 / 2 results
research Evaluation of Serum Ferritin, Creatinine, and Liver Enzymes in Patients with Beta-Thalassemia After Administration of Deferasirox
Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.